share_log
Reuters ·  May 4 08:00
MindMed Presents Phase 2B Study of Mm120 for Generalized Anxiety Disorder (Gad) at American Psychiatric Association (Apa) Annual Meeting in New York
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment